And Now... What Amgen Lobbied For, In Q1 2017...

But first, my earlier off-hand remark this morning, about Amgen's overall spending level was inaccurate: it doesn't really stay level at around $3 million. In fact, like Pfizer, Amgen has ramped up (increased) its spending this year, compared to last year's Q1 (so I've edited my earlier remarks). It increased by over a million dollars -- but Amgen has not spent (proportionately) the way Pfizer has, over the last three years. And, as a reminder, Merck actually cut its spend in half in Q1 2017 -- compared to last year's Q1.

So -- to recap: Merck's lobby topics/issues list is in blue text, below -- Pfizer's; in orange -- and Amgen's is in green, immediately below. Once again, though -- note how much more "medicines focused" Amegen (like Merck) is in its spend -- and how much more Pfizer focuses on "financial engineering" issues:

. . . .▲ Biosimilars, no specific bill; PDUFA, no specific bill; Orphan Drugs, no specific bill; Prescription drug value issues, no specific bill; S. 469 Affordable and Safe Prescription Drug Importation Act; H.R. 1245 Affordable and Safe Prescription Drug Importation Act; S.Con.Res.3 A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2017 and setting forth the appropriate budgetary levels for fiscal years 2018-2026 (importation, non-interference); H.R. 1628 American Health Care Act; repeal/replace ACA. . . .

▲ Medicare Part B (Average Sales Price) (Medicare Program Part B Drug Payment Model proposed rule); Medicare Part D (rebates). . . .

▲ International tax issues, including: Tax Reform; and Puerto Rico Tax Incentives. . . .

▲ Provide advice and strategic counsel with regard to regulations that could impact biopharmaceutical manufacturers generally and Amgens pecifically, including Medicare Part D, Medicare Part B, Health Care Reform, Medicaid, 340b, FDA regulatory issues, and corporate tax reform. . . .

▲ S. 469 Affordable and Safe Prescription Drug Importation Act, issues related to pharmaceutical pricing. . . .

Now you know. Onward. Puzzling out the radio silence -- will just wait until something happens to look into it, I guess. . . . .

नमस्ते